Novonesis Group Due Diligence

Run due diligence on Novonesis Group: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Novo Nordisk Foundation (Denmark) · www.novonesis.com · 19 vendors

Novonesis is a leading global biosolutions company formed through the combination of Chr. Hansen and Novozymes in 2024. The company leverages microbiology and enzymes to develop and manufacture biosolutions across more than 30 industries, including food and beverages, human health, household care, bioenergy, and agriculture. With approximately 11,000 employees worldwide, Novonesis helps customers produce and consume more sustainably by replacing chemical and fossil-based inputs with biological alternatives.

Resilience scores

Technology vendors

Insights

Last updated 2026-09-13 · revision 7

19 direct vendors, 200 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

11 in-scope frameworks identified; showing 3.

China's 'Three New Foods' Regulations — No public evidence

With a regional headquarters, R&D, and manufacturing in China, Novonesis is subject to China's regulations for new food ingredients, additives, and packaging materials when introducing new products to the Chinese market.

Evidence: https://www.khlaw.com/insights/navigating-food-approvals-china-ingredients-and-additives-finished-foods, https://www.proregulations.com/china-novel-food-ingredients-compliance.html, https://www.norceresearch.no/en/news/focusing-on-risks-not-hazards-can-pave-the-way-for-smaller-enzyme-producers, https://www.biosafe.fi/insight/the-eus-stance-on-genetically-modified-microorganisms-gmms, https://www.zmuni.com/en/service/2237/, https://en.reach24h.com/news/industry-news/food/china-three-new-foods-regulatory-framework-approvals

SOC 2 (source) — No public evidence

The need for a SOC 2 report would depend on whether Novonesis provides services that involve processing or storing customer data, and if their customers require such assurance.

CSRD (source) — Evidence found

Novonesis is a large company headquartered in the EU and is therefore subject to the Corporate Sustainability Reporting Directive.

Financials

Three-year financials

Financial Resilience Score: 8/10

Novonesis demonstrates strong financial resilience as the global #1 player in enzymes and microbial cultures following the January 2024 merger of Novozymes and Chr. Hansen. The combined entity benefits from adjusted EBIT margins of ~25-27%, among the strongest in specialty industrial biotech, supported by proprietary strain and enzyme IP that creates structural pricing power. Gross margins are protected by high switching costs as products are embedded in customers' continuous production processes across detergents, dairy cultures, baking, and animal feed. The balance sheet is solid with an investment-grade-style profile. While leverage rose to finance the merger, cash conversion remains strong (legacy Novozymes generated >DKK 3B in free cash flow). Equity stepped up dramatically at merger close to ~DKK 80B+ from the issuance of ~366 million new B-shares to former Chr. Hansen shareholders. Anchor ownership by Novo Holdings A/S (Novo Nordisk Foundation) provides long-term stability. Revenue diversification across food & beverage, household care, agriculture, bioenergy, and human/animal health markets limits cyclicality. Management targets 6-8% organic revenue growth annually with adjusted EBIT margin expansion toward high-20s%. Key risks include integration execution, customer concentration in household care (P&G, Unilever, Henkel), bioenergy cyclicality, FX exposure (DKK reporting vs USD/EUR revenue), and significant PPA amortization drag on reported earnings.

Key strengths: Global #1 position in enzymes and microbial cultures post-merger, Adjusted EBIT margins of ~25-27%, top-tier in specialty biotech, Diversified end-markets across food, household care, agriculture, bioenergy, Recurring revenue character with sticky customer demand, Strong free cash flow generation (>DKK 3B historically at Novozymes), Anchor shareholder Novo Holdings A/S providing long-term stability, Proprietary strain and enzyme IP creating defensible moat

Risk factors: Integration execution risk from combining two large organizations, Customer concentration in household care (P&G, Unilever, Henkel), Bioenergy/ethanol demand cyclicality and policy dependence, FX risk: DKK reporting vs USD/EUR/EM currency revenues, PPA amortization drag on reported EBIT and net income for years, Agriculture/BioAg partnerships underperforming initial expectations, Elevated leverage post-merger requiring deleveraging

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report